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practicable, dose-banding approaches are currently being introduced in many clinical cen-
tres. The present study aimed to determine the potential impact of using recently devel-
oped National Health Service in England (NHSE) dose-banding tables in a paediatric
setting.
Methods: Using pharmacokinetic parameters obtained from 385 drug administrations in
352 children aged from 1 month to 18 years, treated with five drugs (dactinomycin,
busulfan, carboplatin, cyclophosphamide and etoposide), individual exposures (area under
the plasma drug concentration versus time curve; AUC) obtained using doses rounded ac-
cording to the published NHSE tables were calculated and compared with those obtained
by standard dose calculation methods.
Results: For all five drugs, the relative variation between the NHSE dose and the recom-
mended dose (RecDose) (standard individually calculated dose) was between 6% and
þ5% as expected. In terms of AUC, there was no statistically significant difference in pre-
cision between exposures obtained by the RecDose and those obtained with dose banding
(absolute value of relative difference 15e34%).er Research Centre of Toulouse), Equipe 14 (Laboratoire de Pharmacologie e IUCT-O), 1 Avenue Ire`ne
France.
g@univ-tlse3.fr (M. White-Koning).
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M. White-Koning et al. / European Journal of Cancer 91 (2018) 56e67 57Conclusion: Based on pharmacokinetic data for these five drugs, the results generated sup-
port the implementation of NHSE dose-banding tables. Indeed, inter-patient variability in
drug clearance and exposure far outweighs the impact of relatively small drug dose
changes associated with dose banding.
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Drug dosing in oncology has historically been based on
the body surface area (BSA) of the patient being treated
[1]. According to the theory that larger patients have a
higher elimination capacity, it is assumed that these
patients need to be given higher doses than smaller pa-
tients to achieve comparable drug concentrations. For
many drugs, plasma drug exposure (i.e. area under the
plasma drug concentration versus time curve; AUC) is
related to both toxicity and efficacy [2]. However, there
is little or no direct correlation between BSA and AUC
for most cytotoxic drugs, especially in adults [3]. It is
arguably, therefore, somewhat surprising that the ma-
jority of anticancer drugs are still dosed based on an
absolute calculation from BSA. Dose banding has
recently been proposed to optimise chemotherapy
preparations [4,5], with ranges (or bands) of BSA, and
corresponding midpoints of each band being predefined.
The individual dose for a particular patient is calculated
according to a single BSA value per band, usually the
midpoint of the band in which the actual BSA of the
patient lies. In a recent retrospective study, there was no
significant difference in precision in reaching the target
AUC for the AUC obtained by either dose banding or
strict BSA-based dosing for 1012 adult patients treated
with one of six anticancer drugs [6].
Many hospitals in England treating adult patients
have now adopted a system of dose banding for systemic
anti-cancer treatment (SACT), developed by NHS
England’s Medicine Optimisation and Chemotherapy
Clinical Reference Groups [7]. In the National Health
Service in England (NHSE) dose-banding system,
calculated drug doses are grouped and rounded to a set
of predefined doses. Each series of consecutive dose(s) is
called a ‘band’, with the dose to which they are rounded
towards being the ‘banded dose’. The NHSE bands have
a maximum of 6% variance from the actual dose
calculated, are defined by ‘measurable’ drug volume
rather than a dose in milligrammes, and volumes
consistent with normal vial sizes have been used to
minimise waste where possible. Thanks to this system,
chemotherapy provision can be rationalised and drugs
with sufficient long-term stability can be prepared in
advance of treatment. For doses that fall within
commonly used dose bands, this can help rationalise
chemotherapy service provision by enabling production,within a licenced hospital aseptic unit, or procurement
from external compounding units, of standardised
ready-to-use products. For less common dose bands,
individualised dose preparation will still be required.
The main advantages of this dose-banding approach
include reduced patient waiting times and improved
capacity planning of pharmacy production. Additional
benefits include a reduced potential for medication er-
rors, reduced drug wastage and prospective quality
control of preparations. As recommended by the NHSE
Clinical Reference Group, the national dose-banding
tables are to be used by Hospital Trust Pharmacy Teams
to ensure a standard approach to dose banding of
chemotherapy across all hospitals. The initiative is
initially focused on a relatively small number of
commonly used drugs and is anticipated to help the
NHSE to achieve improved values through the ability to
purchase standard off-the-shelf products.
Although this approach has been demonstrated to be
viable in adults, in children, the issue of chemotherapy
dosing is rendered even more complex by develop-
mental changes in organ function and by the ontogeny
of drug metabolism and renal excretion, in addition to
other sources of variability which also exist in adults,
such as pharmacogenetic differences in drug disposition
[8,9]. Also, as the correlation between clearance and
BSA or weight is better in children than in adults, it is
important to conduct specific analyses on the accept-
ability of dose banding in the paediatric setting.
Furthermore, protocol chemotherapy doses in paediat-
rics are often made on pragmatic empirical grounds,
rather than on a sound pharmacological rationale,
leading to the utilisation of diverse regimens, some
based on BSA and others based on body weight. Of
particular concern are the conversion rules from BSA-
based drug dose regimens to weight-based dose regi-
mens, as applied to the treatment of children under a
certain age (e.g. less than 12 months) or under a certain
weight (e.g. less than 10 or 12 kg) at seemingly arbitrary
boundaries [9]. Thus, chemotherapy-dosing approaches
designated for infants and young children in particular
may lead to considerable inter-individual variability in
drug exposure. This has recently been highlighted for
the widely used anticancer drug carboplatin, with TDM
approaches recommended over the variable BSA- or
body weightebased dosing regimens previously
employed [10].
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the dose-banding tables developed by the NHSE can be
safely used in paediatric patients, according to phar-
macokinetic criteria determined from previously pub-
lished clinical trials. The individual exposures (AUC
values) obtained using doses banded according to the
NHSE tables (or banded using the same calculation
method) were calculated and compared with those ob-
tained with doses calculated according to standard
methods for five commonly used anticancer drugs
(dactinomycin, busulfan, carboplatin, cyclophospha-
mide and etoposide) administered to a total of 352
children and for which pharmacokinetic data were
available from previously published paediatric studies.2. Materials and methods
2.1. Patient eligibility and treatment
Our study included data from 352 children between the
ages of 1 month and 17.7 years treated with at least one
of the following five drugs: dactinomycin (n Z 122),
busulfan (oral administration: nZ 25, intravenous (IV)
administration: n Z 58), carboplatin (n Z 69), cyclo-
phosphamide (n Z 82) and etoposide (n Z 29). All the
children were included in clinical research studies, the
details and conclusions of which have been published
previously in all but one case [11e16]. Exact doses
administered and basic descriptive variables for all the
children were available from each of these studies.
Unless otherwise stated, in all of the studies, the
pharmacokinetic parameters (including individual drug
clearance values) were derived from individual plasma
concentration versus time profiles by fitting a population
pharmacokinetic model to the data using NONMEM,
version 6 or 7.2 [17].2.2. Dactinomycin
Of the 122 patients included in the present work, six
patients were part of a pilot study published in 2005 [11]
(Act D PK 1) and the remaining 116 patients were from
a follow-up study published in 2014 [12] (Act D PK 2).
In Act D PK 1, dactinomycin (Act D) was adminis-
tered as an IV bolus at doses between 0.7 and 1.5mg/m2 as
part of the standard chemotherapy regimen that each
patient was receiving. Blood samples for measurement
were obtained from a central line before administration
and at 15 and 30 min and 1, 2, 4, 6 and 24 h after
administration. Plasma concentrations of dactinomycin
were measured using a validated liquid chromatography-
mass spectrometry (LC/MS) assay. Pharmacokinetic
modelling and parameter estimation were carried out
using WinNonlin Professional, version 3.1 software
(Pharsight Corp, Mountain View, CA).In Act D PK 2, dactinomycin was administered
intravenously (1e5 min) at doses between 0.4 and
1.6 mg/m2, with maximum dose capped at 2 mg for
larger children. The dose of dactinomycin administered
was adjusted for infants aged <1 year, or weighing
<10 kg in body weight, with protocol doses of
0.02e0.05 mg/kg. Blood samples for measurement were
collected from a central venous line before administra-
tion and at 5, 15 and 30 min and 2, 4, 8, 24 and 26 h
after administration. Plasma concentrations of dacti-
nomycin were obtained using a modified LC/MS assay,
and population pharmacokinetic modelling was carried
out as described in Ref. [12].2.3. Busulfan
Busulfan data were obtained from patients being treated
on the High Risk NeuroBLastoma trial-1 (HR-NBL-1)
study [14], with busulfan administered four times daily
for 4 days. Oral busulfan (25 patients) was administered
at a dose of 30 mg/m2 (1.45 mg/kg) for children <12 kg
and at a dose level of 37.5 mg/m2 (1.55 mg/kg) for pa-
tients >12 kg (as these patients were in the original
study, we decided to include them in the present analysis
using the same banding method as the parenteral
form). Intravenous busulfan (58 patients) was adminis-
tered over 2 h at five fixed dose levels from 0.8 to 1.2 mg/
kg, according to body weight and without dose adap-
tation. Blood samples were obtained before adminis-
tration and at 2, 4 and 6 h after the start of
administration on day 1 of treatment. An additional
sample was obtained before the start of administration
for doses 5, 9 and 13. Busulfan analysis was carried out
using gas chromatography-mass spectrometry [18].2.4. Carboplatin
Of the 69 patients receiving carboplatin, 28 were from
the MMT 98 study of soft-tissue sarcoma patients [19],
19 patients were from the European Infant Neuroblas-
toma Study (INES) study of children aged <1 year at
diagnosis and weighing <12 kg at treatment [16], and
the remaining 22 patients were from the INF PK/PG
study (REC 06/MRE04/46; CTA: 17136/0245/001; Eu-
ropean Clinical Trials Database (EUDRACT): 2006-
002845-36), an unpublished study investigating the
pharmacokinetics of several anticancer drugs in children
aged 0e2 years (doses described in detail in Table 1).
In the MMT 98 study, 28 patients were treated with
high-dose carboplatin administered as a 1 h IV infusion,
with the initial dose based on renal function, to achieve
cumulative target AUC values of 20 mg/mL min over a
5-day treatment period. Dose adjustment was carried
out based on observed individual daily AUC values to
obtain the defined target exposure. Blood samples for
pharmacokinetic analysis were obtained from a central
Table 1
Patient and drug characteristics for each drug group.
Drug (Total number
of drug doses)
Studies Dosing regimen Number of patients Age (years) Weight (kg)
Median (minemax) Median (minemax)
Actinomycin D Act D PK 2 (Hill et al., 2014) 0.025 mg/kg 2 4.6 (0.4e9) 15.0 (9e21)
(N Z 122) n Z 116 0.030 mg/kg 22 1.6 (0.8e15) 10.9 (7e75)
0.045 mg/kg 34 3.9 (0.3e17) 16.2 (5e50)
0.05 mg/kg 4 1 (0.9e1.2) 8.8 (8e10)
0.75 mg/m2 17 8.1 (2e17) 25.4 (13e77)
1.5 mg/m2 36 5.5 (2e14) 19.0 (11e63)
Unknown 1 16 e 59.5 e
Act D PK 1 (Veal et al., 2005) 0.030 mg/kg 1 15.5 e 63.0 e
n Z 6 0.045 mg/kg 1 3.2 e 16.3 e
0.75 mg/m2 1 17.7 e 62.5 e
1.5 mg/m2 3 6.3 (3e15) 30.5 (10e33)
Busulfan HR-NBL-1 (Veal et al., 2012)
(N Z 83) Oral busulfan: n Z 25 30 mg/m2 8 2.1 (2e3) 11.1 (10e12)
37.5 mg/m2 17 3.9 (3e8) 16.6 (12e23)
IV busulfan: n Z 58 (þ20a) 1.0 mg/kg 4 1.0 (1e9) 8.5 (8e25)
1.1 mg/kg 14 4.5 (2e7) 17.8 (13e21)
1.2 mg/kg 39 3.0 (1e6) 13.9 (10e20)
1.3 mg/kg 1 5.5 e 14.3 e
Carboplatin INES (Veal et al., 2010) 3.75 mg/kg 1 0.2 e 4.8 e
(N Z 69) n Z 19 5 mg/kg 1 0.5 e 7.4 e
6.6 mg/kg 17 0.8 (0.2e1) 8.7 (5e11)
INF PK/PGa 6.6 mg/kg 4 0.6 (0.5e1) 8.6 (7e11)
n Z 21 300 mg/m2 1 1.9 e 11.8 e
500 mg/m2 2 1.9 (1.8e2) 12.5 (12e13)
550 mg/m2 3 1.5 (0.6e2) 8.7 (8e12)
Unknown 11 0.7 (0.1e2) 8.8 (4e12)
MMT 98 (Veal et al., 2007)
n Z 28(þ1b) GFR-based 29 12.0 (1e17.5) 38.5 (10e88)
Cyclophosphamide INF PK/PGa 5 mg/kg 2 0.4 (0.4e0.4) 8.3 (7e9)
(N Z 82) n Z 21 10 mg/kg 3 1.7 (0.8e2) 11.8 (9e13)
36 mg/kg 2 0.5 (0.3e1) 7.1 (6e9)
45 mg/kg 4 1.9 (1e2) 12.0 (11e16)
750 mg/m2 3 0.7 (0.7e1) 8.7 (7e10)
330 mg/m2 1 1.9 e 11.8 e
1500 mg/m2 2 1.9 (1.8e1.9) 12.9 (10e16)
Unknown 4 0.9 (0.8e1) 9.0 (8e11)
Cyclo NHL (Veal et al., 2016)
n Z 47 250 mg/m2 47 11 (3e17) 36.2 (13e82)
MMT 98 (Chinnaswamy, 2011)
n Z 14 2 g/m2 14 13.0 (5e17.5) 48.3 (22e85)
Etoposide INES (Veal et al., 2010)
(N Z 29) n Z 11 5 mg/kg 11 0.9 (0.2e1) 8.8 (5e10)
INF PK/PGa 3.3 mg/kg 2 0.3 (0.1e0.4) 4.6 (3e6)
n Z 18 5 mg/kg 3 0.5 (0.4e0.7) 7.4 (7e8)
7.5 mg/kg 1 1.5 e 10.6 e
12 mg/kg 2 0.8 (0.8e0.8) 8.6 (8e9)
75 mg/m2 1 1.9 e 11.8 e
100 mg/m2 1 1.8 e 10.8 e
120 mg/m2 3 1.3 (1e2) 11.0 (11e12)
150 mg/m2 3 1.3 (1e2) 12.0 (5e15)
Unknown 2 1.2 (0.9e2) 9.6 (7e12)
IV, intravenous.
Note: some patients were treated with more than one drug so their data appears in more than one drug group.
a These patients are from unpublished studies.
b Patient from INF PK/PG study.
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after the start of infusion.
In the INES study, carboplatin (6.6 mg/kg/day; 1 h
IV infusion) and etoposide were co-administered to the19 patients on each of 3 days of treatment. Blood
samples for measurement of carboplatin concentrations
were taken before infusion and at 30 min, 1 h and 2 h
after the start of administration.
M. White-Koning et al. / European Journal of Cancer 91 (2018) 56e6760In both of these studies, the sampleswere centrifuged to
obtain plasma ultrafiltrate for the determination of free
carboplatin levels. Platinum pharmacokinetic analyses
were carried out by flameless atomic absorption spectro-
photometry.Unbound platinum levels were determined in
plasma ultrafiltrate samples as described in Ref. [20].
2.5. Cyclophosphamide
Of the 82 patients receiving cyclophosphamide, 47 pa-
tients were from the Cyclo NHL study of B-cell non-
Hodgkin lymphoma patients [13]; Veal et al., 2016, 14
were from the MMT 98 study [15], and the remaining
21 patients were from the unpublished Infant Phar-
macoKinetics/PharmacoGenetics (INF PK/PG) study
involving children aged 0e2 years (doses described in
detail in Table 1).
In the Cyclo NHL study, cyclophosphamide (250 mg/
m2) was administered as a 15 min IV infusion twice daily
on days 2, 3 and 4 of treatment as part of the COPADM
regimen (i.e. with vincristine, prednisolone, doxorubicin,
methotrexate, folinic acid and intrathecal methotrexate/
hydrocortisone). Blood samples were obtained before
administration of the first dose of cyclophosphamide on
day 2, at the end of infusion and at 1, 2, 4, 6 and 12 h
after the start of infusion. Concentrations of cyclo-
phosphamide were measured using a validated LC/MS
method [15].
2.6. Etoposide
In the INES study, etoposide (5 mg/kg/day; 2 h IV
infusion) and carboplatin were co-administered to the
patients on each of 3 days of treatment. Blood samples
for the measurement of etoposide concentrations were
taken before infusion and at 1 h, 2 h and 4 h after the
start of administration from 11 patients. Etoposide
levels were determined using an API 2000 LC/MS/MS
after extraction from plasma samples. The remaining 18
patients treated with etoposide were from the unpub-
lished INF PK/PG study (doses described in detail in
Table 1).
2.7. Calculation of drug doses using the NHSE dose-
banding tables
For each drug and dosing regimen (except Glomerular
Filtration Rate (GFR)-based carboplatin), the recom-
mended dose (RecDose) was calculated as the dosing
regimen stated in the protocol adapted to child weight
[RecDose Z dosing regimen (mg/kg)  weight (kg)] or
child BSA [RecDose Z dosing regimen (mg/m2)  BSA
(m2)] as defined in the treatment protocol, with BSA
calculated using body weight/BSA conversion tables
provided by the Children’s Cancer and Leukaemia
Group Chemotherapy Standardisation Group [21]. For
carboplatin administered according to patient GFR, thetarget AUC was 4 mg/mL min, and the RecDose was
calculated according to the formula used in MMT 98:
RecDose (mg) Z 4 (mg/mL min)  [GFR (mL/
min) þ 15 (ml/min/m2)  BSA (m2)].
For each patient, the dose which would have been
administered using the NHSE rounding tables [7] was
obtained by taking the RecDose and finding the corre-
sponding band dose given in the appropriate table (6 mg/
mL table for busulfan, 10 mg/mL table for carboplatin
and 20 mg/mL table for cyclophosphamide and etopo-
side). Once reconstituted, dactinomycin has a concentra-
tion of 0.5 mg/mL; however, there is no NHSE dose-
banding table published yet for this concentration. In
addition, some of the doses administered for busulfan
were below those given in the published tables. In both
these cases, we were able to use unpublished tables pro-
vided by the NHSE Chemotherapy Dose Standardisation
Group which were banded according to the same calcu-
lation method (see tables in supplementary data). This
rounded dose was then referred to as the NHSE dose.
2.8. Impact of dose banding on patient treatment
The relative difference between each dose calculation
method and the recommended dose (RecDose) was
calculated in the following way: Relative difference Z
([DoseStudiedeRecDose]/RecDose)  100; where Dos-
eStudied is the actual dose administered (ActualDose) or
the NHSE dose. The absolute value of relative difference,
which is Z (jDoseStudiedeRecDosej/RecDose)  100,
was also calculated.Meanand standarddeviation for these
quantities were given as well as minimum and maximum
values for relative difference. As an indication of dose
modification, the percentage of values where the absolute
value of relative difference was greater than 5% was also
given.
For each drug and each dosing regimen, the target
AUCwas calculated by dividing theRecDose by themean
value of observed clearance (CL) expressed in mL/min:
target AUC Z RecDose (mg)/mean observed CL (mL/
min) (except for GFR-based carboplatin where target
AUC Z 4 mg/mL min as defined in the MMT 98 study
protocol). For busulfan, as well as the theoretical indi-
vidual target AUC calculated as described above, we also
described percentage of AUC values falling within the
‘therapeutic window’ AUC of 900e1500 mM min
(0.22e0.37 mg/mL min) which has been defined by TDM
approaches for busulfan [22,23]. For each patient,
theAUC corresponding to theActualDose was calculated
as AUC_ActualZ ActualDose/individual clearance and
the AUC corresponding to theNHSE dose was calculated
as AUC_NHSE Z NHSE dose/individual clearance.
The percentage error of AUC (p) corresponding to each
dose was calculated: e.g. [(AUC_NHSEetarget AUC)/
target AUC]  100. The absolute value of relative differ-
ence (jAUC_NHSEetarget AUCj/target AUC)  100
was also calculated. The precision (root mean square
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was calculated in the following way: RMSE (%)
Z
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiPn
iZ1ðpÞ2=n
q
, where n is the number of patients in
each drug group.
The potential impact of using NHSE dose banding
was evaluated in three different ways. First, we calcu-
lated the relative difference and absolute value of the
relative difference (described above) between the NHSE
dose and the RecDose. Second, the absolute value of the
relative difference in AUCs obtained using the NHSE
dose and the RecDose was compared using the paired
Student t-test or the Wilcoxon signed-rank test
(depending on data normality). Finally, the paired Stu-
dent t-test or Wilcoxon signed-rank test was used to
compare the precision (RMSE) of the AUCs obtained
using the NHSE dose to the precision of the AUC ob-
tained with the RecDose.
3. Results
3.1. Patient characteristics and treatment
The study included 385 drug administrations from 352
children aged between 1 month and 17.7 years
(median Z 3.6 years), being treated for cancer with at
least one of the following drugs: dactinomycin (122 drug
administrations), busulfan (83), carboplatin (69), cyclo-
phosphamide (82), and etoposide (29). Some children
were treated with several drugs: 11 children from the
INES study were treated with carboplatin and etoposide,
11 children from the MMT 98 study were treated with
carboplatin and cyclophosphamide, and in the INF PK/
PG study, the treatment combinations were carboplatin,
cyclophosphamide and etoposide (1 patient), cyclo-
phosphamide and etoposide (2 patients), carboplatin and
cyclophosphamide (2 patients) and carboplatin and eto-
poside (5 patients). These children were treated for a
wide range of tumours including neuroblastoma (117
children), B-cell non-Hodgkin’s lymphoma (47), Wilms
tumour (45), rhabdomyosarcoma (31), other soft-tissue
sarcomas (32) and Ewing’s sarcoma (26) (see Table 2 for
details of all tumour types). As can be seen in Table 1,
even for patients treated within the same study, there was
a wide variety of dosing regimens used for each drug.
Some dosages were weight-based, with others based on
BSA or GFR (for carboplatin). In terms of age, the
etoposide group and the non-GFR-based carboplatin
group were all younger than 2 years, and the children in
the busulfan group were all younger than 8 years. In the
other drug groups, the age range was wider, extending
from infants to teenagers.
3.2. Pharmacokinetics and dosing
As can be seen in Fig. 1, the inter-individual variability
in individual mean clearance values ranged from 22%(coefficient of variation) for busulfan (IV) to 61% for the
infant cyclophosphamide group. With the exception of
busulfan (IV) and GFR-based carboplatin, all other
drug groups exhibited inter-individual variabilities
greater than 25%.
Over all five drugs studied, the relative variation in
dose between the ActualDose and the RecDose ac-
cording to the stipulated dosing regimen ranged between
43% and þ26% (Table 3). In contrast, the difference
was between 6% and þ5% for the NHSE-rounded
dose relative to the RecDose (Table 3), which was to be
expected as the NHSE tables were constructed for the
variation to be less than 6%. These differences were
small for busulfan, cyclophosphamide and etoposide
(between 7% and þ7%) but were much greater for
carboplatin (GFR-based dosing between 43% and
þ1% and other dosing regimens between 32% and
þ3%) and dactinomycin (between 14% and þ26%).
These observed discrepancies from the stipulated dosing
regimens may represent dose adjustments relating to
dose capping, liver impairment, co-morbidities or in the
case of carboplatin, cautionary approaches to initial
dosing ahead of adaptive dosing. In terms of AUC and
the capacity to attain the target AUC, there was no
statistically significant difference in precision for any of
the five drugs between the plasma exposure obtained
with the standard dosing method (Actual dose) and that
obtained with the NHSE dosing method, with RMSEs
ranging from 21% (for carboplatin) to 57% (for cyclo-
phosphamide) (Table 4). Fig. 2 shows the frequency of
percentage errors between individual AUC and target
AUC using standard dosing methods (Actual dose) or
the NHSE dose-banding method for each drug, with
very similar distributions except for carboplatin, where
the distributions were more variable. For busulfan, the
proportion of AUC values falling within the therapeutic
window of 900e1500 mM min was comparable, which-
ever dosing method was used. Of relevance to the utility
of NHSE dose banding, for patients treated with IV
busulfan, 74% of their actual AUC values were within
the therapeutic window, whereas 79% of the AUC
values calculated with the NHSE dosing method were
within the therapeutic window. Fig. 3 shows the fre-
quency of percentage errors observed in the ActualDo-
ses as compared with the proposed NHSE dose-banding
doses (NHSE Dose) for all five drugs studied. Fig. 4SA
and 4SB are given as supplementary data and show, for
each of the five drugs under study, clearance (mL/min)
versus body weight (kg) (Fig. 4SA) and BSA (m2)
(Fig. 4SB).4. Discussion
Although BSA-based dosing has been criticised for
many years now [24], because of the weak correlation
between drug clearance (and thus conversely systemic
Table 2
Tumour types in each drug group.
Drug Tumour Frequency Percent
Dactinomycin (n Z 122) Wilms 45 36.9
Rhabdomyosarcoma 31 24.6
Ewing’s sarcoma 25 20.5
Alveolar rhabdomyosarcoma 7 5.7
Embryonal rhabdomyosarcoma 6 4.9
Rhabdomyosarcoma of prostate 1 0.8
Embryonal sarcoma of liver 1 0.8
Malignant mesenchymal tumour 1 0.8
Metastatic pancreatic neuroendocrine tumour 1 0.8
Metastatic non-rhabdomyosarcoma 1 0.8
Nephroblastoma 1 0.8
Non-rhabdomyosarcoma 1 0.8
Paraspinal undifferentiated sarcoma 1 0.8
Pleuropulmonary blastoma 1 0.8
Soft-tissue sarcoma 1 0.8
Busulfan (n Z 83) Neuroblastoma 83 100
Carboplatin (n Z 69) Soft-tissue sarcoma 28 40.6
Neuroblastoma 26 37.7
Retinoblastoma 4 5.8
Bilateral retinoblastoma 2 2.9
Ependymoma 1 1.5
Germ-cell tumour 1 1.5
Optic chiasm Glioma 1 1.5
PNET supratentorial 1 1.5
Rhabdoid 1 1.5
Rhabdoid e kidney 1 1.5
Rhabdoid sarcoma 1 1.5
Vaginal yolk sac tumour 1 1.5
Visual pathway glioma 1 1.5
Cyclophosphamide (n Z 82) B-cell non-Hodgkin lymphoma 47 57.3
Soft-tissue sarcoma 14 17.1
Acute lymphoblastic leukaemia 8 9.8
Neuroblastoma 6 7.3
Astrocytoma 1 1.2
Ependymoma 1 1.2
Optic chiasm glioma 1 1.2
PNET supratentorial 1 1.2
Posterior fossa ATRT 1 1.2
Rhabdoid e kidney 1 1.2
Rhabdomyosarcoma 1 1.2
Etoposide (n Z 29) Neuroblastoma 18 62.1
Retinoblastoma 4 13.8
Acute lymphoblastic leukaemia 1 3.5
Astrocytoma 1 3.5
Ewing’s sarcoma 1 3.5
Germ-cell tumour 1 3.5
Rhabdoid e kidney 1 3.5
Teratoma 1 3.5
Yolk sac tumour 1 3.5
Note: some patients are included in more than one treatment group.
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adults and children. In the paediatric setting, variations
in inter-individual metabolism due to developmental
changes, in addition to other sources of variability, can
result in significant differences in drug exposure for
children compared with adults treated at the same dose
[25]. Pharmacokinetic studies have shown that children
receiving the same dose scaled to BSA or body weight
commonly exhibit large differences in systemic drug
exposure, which in turn may be associated with sub-therapeutic drug concentrations or overexposure [26].
Another significant problem is the use of arbitrary dose
reductions for infants, using either a percentage ac-
cording to age (e.g. 50% dose reduction under 12
months) or body weight (10 kg or 12 kg thresholds are
commonly used), based on fears of an increased sus-
ceptibility to toxicity but with little scientific justification
[27]. The dearth of information concerning the phar-
macokinetics of many anticancer drugs, particularly for
infants below the age of 12 months, is linked to a lack of
Table 3
Percentage dose variation of actual dose administered and NHSE dose-banding method relative to recommended dose.
Drug N Actual dose NHSE dose
Absolute value of relative
difference
Relative
difference
Absolute value of relative
difference
Relative difference
Mean (SD) 5%a Min Max Mean (SD) 5%a Min Max
Dactinomycin 121 4.0 (4.8) 26 14 +26 2.3 (1.3) 1 5 +5
Busulfan 83 1.6 (1.6) 5 7 +7 1.9 (1.2) 1 4 +5
Busulfan (oral) 25 1.9 (1.9) 8 5 +7 1.9 (1.3) 4 2 +5
Busulfan (IV) 58 1.5 (1.5) 3 7 +4 1.9 (1.2) 0 4 +4
Carboplatin (other) 29 2.1 (5.8) 0 32 +3 2.6 (1.4) 0 5 +4
Carboplatin (GFR) 16 3.3 (10.6) 6 43 +1 3.3 (1.3) 0 5 +4
Cyclophosphamide 78 0.7 (1.1) 0 4 +5 2.3 (1.4) 4 6 +5
Etoposide 27 1.1 (1.3) 0 4 +4 2.0 (1.5) 0 4 +5
Relative differenceZðDoseStudiedRecDoseÞRecDose  100 where DoseStudied is Actual dose or NHSE dose.
Absolute value of relative differenceZjDoseStudiedRecDosejRecDose  100.
NSHE, National Health Service in England; SD, standard deviation.
a Percentage of values where absolute value of relative difference is greater than 5%.
Table 4
Differences in plasma exposure (AUC) using each dosing method (Actual dose and NHSE dose) compared with target AUC [recommended dose
(mg)/mean CL (mL/min)].
Drug N AUC with Actual dose AUC with NHSE dose
Absolute value of relative difference Absolute value of relative difference
Mean (SD) RMSE Mean (SD) RMSE
Dactinomycin 121 19.9 (21.2) 29.0 19.2 (19.5) 27.3
Busulfan 82 22.2 (26.8) 34.7 22.8 (27.2) 35.4
Busulfan (oral) 25 28.4 (20.2) 34.6 29.5 (20.8) 35.8
Busulfan (IV) 57 19.5 (29.0) 34.7 19.9 (29.3) 35.1
Carboplatin (other) 29 16.2 (14.1) 21.3 15.3 (14.4) 20.8
Carboplatin (GFR) 16 22.3 (15.2) 26.7 25.5 (16.4) 30.1
Cyclophosphamide 78 34.0 (45.5) 56.6 34.1 (45.5) 56.6
Etoposide 27 33.4 (39.3) 51.0 34.2 (38.9) 51.2
RMSE, root mean square error; NHSE, National Health Service England; SD, standard deviation
CV= 26%
CV= 48%
CV= 61%
CV= 52%
CV= 39%
CV= 22%
CV= 42%
CV= 23%
0 100 200 300 400
Etoposide (n=29)
Cyclophosphamide other (n=61)
Cyclophosphamide Infant (n=21)
Carboplatin other (n=40)
Carboplatin GFR (n=29)
Busulfan (oral) (n=23)
Busulfan (IV) (n=56)
Actinomycin D (n=121)
Clearance (mL/min/m²)
Fig. 1. Individual mean clearance values (mL/min/m2) according to drug type with coefficient of variation (CV) as measure of variability.
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Fig. 2. Frequency of percentage errors between individual area under the curve (AUC) and target AUC using standard dosing methods
(Actual dose) or NHSE dose-banding (NHS dose) for dactinomycin, busulfan, carboplatin, cyclophosphamide and etoposide. NHSE,
National Health Service England.
M. White-Koning et al. / European Journal of Cancer 91 (2018) 56e6764scientific rationale and standardisation in terms of
dosing regimens. A recent report by Balis et al. (2017)
from the Children’s Oncology Group Chemotherapy
Standardization Task Force, showed once again that
BSA and body weight are inconsistently used across
drugs and treatment protocols (sometimes even within
protocols) to adjust doses for the wide range of body
sizes encountered from birth to adulthood. In the 29
Children’s Oncology Group protocols studied, 11 sets of
criteria using age, weight, BSA or a combination of
these parameters were used for dose modifications as
well as eight dose modification methods.
This heterogeneity in approaches to dosing is
apparent from the current analysis, with a variety of
dosing regimens used for the five drugs even within the
same clinical study or for the same tumour type
(Table 1). Over and above these variations in intended
or ‘recommended dose’ (i.e. the dosing regimen specified
in the protocol), our analysis indicated that there was
also a difference between the actual dose administered
and the recommended dose. Although the absolute
values of mean differences are relatively small
(0.7e3.9%), some individual relative differences are
much larger, with dactinomycin values ranging between
14% and þ26% and carboplatin values down to 43%
for GFR-based carboplatin and 32% for carboplatinbased on other dosing regimens (Table 3). For example,
the patient for whom the relative difference is 43% is
an 11-year-old girl treated for soft-tissue sarcoma who
should have received an initial dose of 526 mg of car-
boplatin based on GFR and the formula used to attain
the target AUC (see Methods section), but the actual
first dose she received was 300 mg. Interestingly, the
dose was increased on subsequent days of treatment as
therapeutic drug monitoring (TDM) was carried out on
this patient to achieve the target AUC, highlighting the
benefits of TDM approaches to treatment in a paediatric
oncology setting [9,27]. It should be noted that this type
of clinical scenario, incorporating an initial lower dose
followed by adaptive dosing, could be applied equally to
both standard dosing and dose-banding approaches.
The absolute value of relative differences in plasma
exposure between the target AUC (based on the recom-
mended dose) and the actual AUC, ranged from 20% for
dactinomycin and busulfan administered by IV to 34% for
cyclophosphamide. These mean differences can result
from differences in doses as mentioned above and inter-
individual variability in terms of drug clearance (see
Fig. 1).
In comparison, the doses which would have been
administered based on the banded doses proposed in the
NHSE tables had relative differences ranging from 6%
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Fig. 3. Frequency of percentage errors observed in the actual doses administered (Actual dose) as compared with the proposed NHSE
dose-banding doses (NHS dose) for dactinomycin, busulfan, carboplatin, cyclophosphamide and etoposide. NHSE, National Health
Service England.
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pected. Importantly, differences between target AUC
values and AUC values which would have been ob-
tained with NHSE dose banding were not statistically
significantly different from the variability in plasma
exposure already observed with current dosing practices
(Table 4). Fig. 2 also shows that the distribution of
percentage errors between individual AUC and target
AUC values is comparable for all five drugs when using
NHSE dose banding and standard dosing methods. For
busulfan, the proportion of AUC values falling within
the therapeutic window of 900e1500 mM min was un-
affected by the dosing method used and was comparable
to that found in the article initially reporting these data
[14]. These results are in agreement with a previously
published retrospective study including 1012 adult pa-
tients treated with one of six anticancer drugs, where the
authors found no significant difference in precision in
reaching the target AUC between dose-banding and
BSA-based dosing [6].
The Chemotherapy Dose Standardisation initiative,
developed by NHS England’s Medicine Optimisation
and Chemotherapy Clinical Reference Groups, has
published dose-banding tables to be used for a number
of drugs by Hospital Trust Pharmacy Teams to ensure
a standard approach to dose banding of SACT acrossall Hospital Trusts [7]. The guiding principle for these
tables was: ‘no target dose of traditional SACT is
greater than 6% of the precise calculated dose
without specific prior agreement and no target dose of
[monoclonal antibodies] used as a SACT is greater than
10% of the precise calculated dose without specific
prior agreement’. Also the dose bands used in these
tables were calculated as a measurable drug volume
rather than a dose in milligrammes, hence they can be
applied to any drug, and volumes which closely match
vial sizes have been used where possible to minimise
waste.
For drugs with sufficient long-term stability, prepa-
ration of commonly banded doses can be carried out in
advance, which can help rationalise chemotherapy ser-
vice provision and reduce patient waiting times. Addi-
tional benefits include a reduced potential for medication
errors, reduced drug wastage, prospective quality control
of preparations and reduced workload for staff. These
will of course also have a positive impact on the overall
cost of chemotherapy for the health service, with the
money saved potentially reinvested into research or other
schemes to improve paediatric cancer care. Pharmacoe-
conomic studies comparing costs with and without the
use of dose banding could be conducted to verify this.
Many of these benefits are not transferable to the
M. White-Koning et al. / European Journal of Cancer 91 (2018) 56e6766paediatric setting as the dose bands used will not be those
commonly used in adults, and final drug volumes of
ready-to-use products may be too high for young pa-
tients to tolerate, thus requiring individualised dose
preparation. In addition, many children with cancer are
treated on clinical trials (national or international) which
may not currently allow dose banding. Nevertheless, for
those centres treating adults, children and young people,
benefits may be seen in the older children, particularly
related to the use of standardised ready-to-use products.
In a recent effort to rationalise and simplify the array
of anticancer drug-dosing methods used in the Children
Oncology Group (COG) trials, the COG’s Chemo-
therapy Standardization Task Force have developed
dosing tables for infants and children with a
BSA<0.6 m2 (which is reached at about 36 months of
age) [9]. The tables are different for each drug and give
doses for defined BSA bands and gradually transition
stepwise from the dose based on body weight using the
30-Rule (dividing the BSA-based dose by 30) to BSA
dosing. Based on data from 1718 infants and children
treated on COG trials, a simple linear regression model
was used to obtain dose values and then dose bands
based on BSA intervals and deliverable drug concen-
trations and volumes. The authors emphasise that these
tables are empirical, and it remains to be determined
whether this infant dosing method provides more uni-
form exposure across patients and over the entire age
range (birth to 36 months) by studying pharmacokinetic
data. Based on pharmacokinetic data from 352 children,
our study supports the implementation of dosing based
on the NHSE dose-banding tables, at least for the five
drugs investigated here (dactinomycin, busulfan, car-
boplatin, cyclophosphamide and etoposide). Further
evaluation of the effect of using dose banding for other
drugs would be needed to confirm these results and
extend them to additional anticancer drugs.
Conflict of interest statement
Caroline Osborne works as a cancer pharmacist for
the NHSE North of England Specialised Commis-
sioning Team (North-West Hub) under a service level
agreement. All the other authors declare no potential
conflicts of interest.Acknowledgements
The authors would like to thank Richard Nuttall
from the Royal Marsden and member of the NHSE
Chemotherapy Dose Standardisation Group for the
provision of NHSE dose-banding information and ta-
bles. This work was supported in part by Cancer
Research UK (CRUK grant number C9380/A25138),
the North of England Children’s Cancer Research Fund
and the Experimental Cancer Medicine CentreNetwork. No funding bodies played a role in the study
design, the collection, analysis or interpretation of data,
the writing of the report or the decision to submit the
article for publication.
Appendix A. Supplementary data
Supplementary data related to this article can be found
at https://doi.org/10.1016/j.ejca.2017.11.029.References
[1] Pinkel D. The use of body surface area as a criterion of drug
dosage in cancer chemotherapy. Cancer Res 1958;18:853e6.
[2] Gurney H. Dose calculation of anticancer drugs: a review of the
current practice and introduction of an alternative. J Clin Oncol
Off J Am Soc Clin Oncol 1996;14:2590e611. https://doi.org/10.
1200/JCO.1996.14.9.2590.
[3] Mathijssen RHJ, de Jong FA, Loos WJ, van der Bol JM,
Verweij J, Sparreboom A. Flat-fixed dosing versus body surface
areaebased dosing of anticancer drugs in adults: does it make a
difference? The Oncologist 2007;12:913e23. https://doi.org/10.
1634/theoncologist.12-8-913.
[4] Plumridge RJ, Sewell GJ. Dose-banding of cytotoxic drugs: a new
concept in cancer chemotherapy. Am J Health Syst Pharm 2001;
58:1760e4.
[5] PouliquenA-L,EscalupL, JourdanN,CottuP,FaureP,Madelaine-
Chambrin I. Dose standardisation of anticancer drugs. Int J Clin
Pharm 2011;33:221e8. https://doi.org/10.1007/s11096-010-9478-6.
[6] Chatelut E, White-Koning ML, Mathijssen RH, Puisset F,
Baker SD, Sparreboom A. Dose banding as an alternative to body
surface area-based dosing of chemotherapeutic agents. Br J
Cancer 2012;107:1100e6. https://doi.org/10.1038/bjc.2012.357.
[7] NHS England National Programmes of Care and Clinical
Reference Groups, https://www.england.nhs.uk/commissioning/
spec-services/npc-crg/group-b/b02/. [Accessed 17 June 2017].
[8] Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL,
Leeder JS, Kauffman RE, et al. Developmental pharmacology e
drug disposition, action and therapy in infants and children. New
Engl J Med 2003;349:1157e67.
[9] Balis FM, Womer RB, Berg S, Winick N, Adamson PC, Fox E.
Dosing anticancer drugs in infants: current approach and rec-
ommendations from the Children’s Oncology Group’s Chemo-
therapy Standardization Task Force. Pediatr Blood Cancer 2017;
64, e26636. https://doi.org/10.1002/pbc.26636.
[10] Veal GJ, Errington J, Hayden J, Hobin D, Murphy D,
Dommett RM, et al. Carboplatin therapeutic monitoring in pre-
term and full-term neonates. Eur J Cancer 2015;51:2022e30.
https://doi.org/10.1016/j.ejca.2015.07.011.
[11] Veal GJ, Cole M, Errington J, Parry A, Hale J, Pearson ADJ,
et al. Pharmacokinetics of dactinomycin in a pediatric patient
population: a United Kingdom Children’s Cancer Study Group
Study. Clin Cancer Res 2005;11:5893e9. https://doi.org/10.1158/
1078-0432.CCR-04-2546.
[12] Hill CR, Cole M, Errington J, Malik G, Boddy AV, Veal GJ.
Characterisation of the clinical pharmacokinetics of actinomycin
D and the influence of ABCB1 pharmacogenetic variation on
actinomycin D disposition in children with cancer. Clin Phar-
macokinet 2014;53:741e51. https://doi.org/10.1007/s40262-014-
0153-2.
[13] Veal GJ, Cole M, Chinnaswamy G, Sludden J, Jamieson D,
Errington J, et al. Cyclophosphamide pharmacokinetics and
pharmacogenetics in children with B-cell non-Hodgkin’s lym-
phoma. Eur J Cancer 2016;55:56e64. https://doi.org/10.1016/j.
ejca.2015.12.007.
M. White-Koning et al. / European Journal of Cancer 91 (2018) 56e67 67[14] Veal GJ, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-
Couanet D, et al. Busulfan pharmacokinetics following intrave-
nous and oral dosing regimens in children receiving high-dose
myeloablative chemotherapy for high-risk neuroblastoma as
part of the HR-NBL-1/SIOPEN trial. Eur J Cancer 2012;48:
3063e72. https://doi.org/10.1016/j.ejca.2012.05.020.
[15] Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ,
Cole M. Pharmacokinetics of cyclophosphamide and its metab-
olites in paediatric patients receiving high-dose myeloablative
therapy. Eur J Cancer 2011;47:1556e63. https://doi.org/10.1016/j.
ejca.2011.03.008.
[16] Veal GJ, Cole M, Errington J, Pearson ADJ, Gerrard M,
Whyman G, et al. Pharmacokinetics of carboplatin and etoposide
in infant neuroblastoma patients. Cancer Chemother Pharmacol
2010;65:1057e66. https://doi.org/10.1007/s00280-009-1111-9.
[17] Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user’s
guides (1989e2009). 2009.
[18] Vassal G, Re M, Gouyette A. Gas chromatographic-mass spec-
trometric assay for busulfan in biological fluids using a deuterated
internal standard. J Chromatogr 1988;428:357e61.
[19] Veal GJ, Errington J, Tilby MJ, Pearson ADJ, Foot ABM,
McDowell H, et al. Adaptive dosing and platinumeDNA adduct
formation in children receiving high-dose carboplatin for the
treatment of solid tumours. Br J Cancer 2007;96:725e31. https:
//doi.org/10.1038/sj.bjc.6603607.
[20] Veal GJ, Dias C, Price L, Parry A, Errington J, Hale J, et al.
Influence of cellular factors and pharmacokinetics on the forma-
tion of platinum-DNA adducts in leukocytes of children receiving
cisplatin therapy. Clin Cancer Res 2001;7:2205e12.[21] CCLG Chemotherapy Standardisation Group, http://www.ouh.
nhs.uk/oxparc/professionals/documents/Body-
surfaceareaCCLGChart1.pdf [Accessed 02 May 2017].
[22] Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG,
Gilmore CE, et al. Association of busulfan area under the curve
with veno-occlusive disease following BMT. Bone Marrow
Transplant 1996;17:225e30.
[23] Slattery JT, Clift RA, Buckner CD, Radich J, Storer B,
Bensinger WI, et al. Marrow transplantation for chronic myeloid
leukemia: the influence of plasma busulfan levels on the outcome
of transplantation. Blood 1997;89:3055e60.
[24] Ratain MJ. Body-surface area as a basis for dosing of anticancer
agents: science, myth, or habit? J Clin Oncol Off J Am Soc
Clin Oncol 1998;16:2297e8. https://doi.org/10.1200/JCO.1998.16.
7.2297.
[25] Norris RE, Adamson PC. Challenges and opportunities in
childhood cancer drug development. Nat Rev Cancer 2012;12:
776e82. https://doi.org/10.1038/nrc3370.
[26] Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN,
Murphy RF, et al. Pharmacokinetics and pharmacodynamics of
oral methotrexate and mercaptopurine in children with lower risk
acute lymphoblastic leukemia: a joint children’s cancer group and
pediatric oncology branch study. Blood 1998;92:3569e77.
[27] Veal GJ, Errington J, Sastry J, Chisholm J, Brock P,
Morgenstern D, et al. Adaptive dosing of anticancer drugs in
neonates: facilitating evidence-based dosing regimens. Cancer
Chemother Pharmacol 2016;77:685e92. https://doi.org/10.1007/
s00280-016-2975-0.
